CORRIGENDUM TO “AN APOLIPOPROTEIN E-BASED THERAPEUTIC
IMPROVES OUTCOME AND REDUCES ALZHEIMER’S DISEASE
PATHOLOGY FOLLOWING CLOSED HEAD INJURY: EVIDENCE OF
[NEUROSCIENCE 144 (2007) 1324–1333]?
H. WANG,a,bL. DURHAM,bH. DAWSON,bP. SONG,a,cD. S. WARNER,a,c,dP. M. SULLIVAN,bM. P. VITEKb,e
AND D. T. LASKOWITZa,b,c,d*
aMultidisciplinary Neuroprotection Laboratories, Duke University Medical Center, Durham, NC 27710, USA
bDepartment of Medicine (Neurology), Duke University Medical Center, Box 2900, Durham, NC 27710, USA
cDepartment of Neurobiology, Duke University Medical Center, Durham, NC 27710, USA
dDepartment of Anesthesiology, Duke University Medical Center, Durham, NC 27710, USA
eCognosci Inc., Research Triangle Park, NC 27709, USA
On page 1326, right column, in the last line of the first full paragraph, it was mistakenly stated that the commercial source of
the A?(1–42) ELISA was BioSource International. Although the TNF? ELISA was from BioSource, the amyloid ?(1–42)
ELISA was from IBL Co., Ltd. (Tokyo, Japan). The commercial kit was for human amyloid ?(1–42) (Catalog No. 17711) and
has 100% cross-reactivity for rat and mouse.
?DOI of original article: 10.1016/j.neuroscience.2006.11.017
*Corresponding author. Fax: ?1-919-684-6514.
E-mail address: firstname.lastname@example.org (D. T. Laskowitz).
Neuroscience 146 (2007) 874
0306-4522/07$30.00?0.00 © 2006 IBRO. Published by Elsevier Ltd. All rights reserved.